Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Visit the company website

 

Bullboard - Investor Discussion Forum Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s):  VYYRF

Healthcare Drug Manufacturers - Specialty & Generic
Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX... see more

TSXV:VM - Post Discussion

Voyageur Pharmaceuticals Ltd > On the move
View:
Post by postie1 on Dec 20, 2022 12:39pm

On the move

Right now VM has a .09 bid with a  .14 ask and a last sale of .105 . Had a bid /ask of .08/.15 a couple of minutes ago
Comment by Budd22 on Dec 20, 2022 12:43pm
56k shares were bought at .16 on the ATS as well. Giddy up
Comment by whitenorth72 on Dec 20, 2022 12:56pm
Can you send me that link?
Comment by Budd22 on Dec 20, 2022 12:59pm
https://www.stockwatch.com/Quote/DetailM.aspx?C:VM   scroll down to see recent buys/sells  
Comment by whitenorth72 on Dec 20, 2022 1:03pm
Thank you things are looking up
Comment by postie1 on Dec 20, 2022 1:11pm
If I am reading that properly there were actually 2 trades at .16. 1 each on two different ATs exchanges.
Comment by biggdogg on Dec 20, 2022 1:18pm
Their Financing is looking extremely good now!!
Comment by lscfa on Dec 20, 2022 3:17pm
First close of PP tomorrow.  Stock being propped up to entice subscribers?
Comment by postie1 on Dec 20, 2022 5:31pm
I would not be surprised if this is already at least 100% sold and just a matter of people getting their paperwork in. It also takes time to distribute the shares and warrants.It will be interesting to see how well received it was. Personally(IMO) I think this was a good Christmas gift for the people who own shares and are eligible to buy. This close to blastoff is a good time to pad your account ...more  
Voyageur Pharmaceuticals Ltd
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.VM

follow v.vm on


PRODUCTS PIPELINE CARBON DRUG PROJECT WHITE PAPER CASE STUDIES MANAGEMENT PRESENTATION

Voyageur Pharmaceuticals Deck 2024..

The Watchlist

Voyageur Pharmaceuticals | The Watchlist
{{currentVideo.videoCaption}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

COMPELLING
VALUE PROPOSITION

  • Only pharmaceutical company in the world that owns long-term supply of barium and iodine
  • Natural barium and iodine resources meet increasingly limited global supply and risk
  • Multi-billion-dollar global market for contrast media
  • Poised to obtain significant market share by offering high-quality, lower-cost products
  • Favorable regulatory pathway allows rapid commercialization
  • Highly experienced team has positioned the company for profitable commercial success

Contact Us

Brent Willis, CEO
Brent@Vpharma.ca

Address:
Suite 1600 Dome Tower, 333 7th Avenue S.W.
Calgary, Alberta
T2P 2Z1